Evidence map›Paper›PMID 12391152›Full record

ArticleMolecular and cellular biology2002

Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage.

Eugene S Kandel, Jennifer Skeen, Nathan Majewski, Antonio Di Cristofano, Pier Paolo Pandolfi, Claudine S Feliciano, Andrei Gartel, Nissim Hay

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and cellular biology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 278 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Eugene S KandelDepartment of Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60607, USA.
Jennifer Skeen
Nathan Majewski
Antonio Di Cristofano
Pier Paolo Pandolfi
Claudine S Feliciano
Andrei Gartel
Nissim Hay
University of Illinois Chicago · USMemorial Sloan Kettering Cancer Center · US

Funding

PI3K/PTEN/Akt signaling and the genesis of cancerR01CA090764 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Nissim Hay · 2001 to 2026
$9.4M
The Role of Akt in Cell Survival and Cell GrowthR01AG016927 · NIA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI HAY, NISSIM · 1998 to 2023
$9.0M
NCI NIH HHS CA90764NCI NIH HHS R01 CA090764NIA NIH HHS AG16927NIA NIH HHS R01 AG016927
6 · The paper itself

Abstract

Activation of Akt, or protein kinase B, is frequently observed in human cancers. Here we report that Akt activation via overexpression of a constitutively active form or via the loss of PTEN can overcome a G(2)/M cell cycle checkpoint that is induced by DNA damage. Activated Akt also alleviates the reduction in CDC2 activity and mitotic index upon exposure to DNA damage. In addition, we found that PTEN null embryonic stem (ES) cells transit faster from the G(2)/M to the G(1) phase of the cell cycle when compared to wild-type ES cells and that inhibition of phosphoinositol-3-kinase (PI3K) in HEK293 cells elicits G(2) arrest that is alleviated by activated Akt. Furthermore, the transition from the G(2)/M to the G(1) phase of the cell cycle in Akt1 null mouse embryo fibroblasts (MEFs) is attenuated when compared to that of wild-type MEFs. These results indicate that the PI3K/PTEN/Akt pathway plays a role in the regulation of G(2)/M transition. Thus, cells expressing activated Akt continue to divide, without being eliminated by apoptosis, in the presence of continuous exposure to mutagen and accumulate mutations, as measured by inactivation of an exogenously expressed herpes simplex virus thymidine kinase (HSV-tk) gene. This phenotype is independent of p53 status and cannot be reproduced by overexpression of Bcl-2 or Myc and Bcl-2 but seems to counteract a cell cycle checkpoint mediated by DNA mismatch repair (MMR). Accordingly, restoration of the G(2)/M cell cycle checkpoint and apoptosis in MMR-deficient cells, through reintroduction of the missing component of MMR, is alleviated by activated Akt. We suggest that this new activity of Akt in conjunction with its antiapoptotic activity may contribute to genetic instability and could explain its frequent activation in human cancers.

Indexed as

Genes, cdcProtein Serine-Threonine KinasesAnimalsCDC2 Protein KinaseCell CycleCell LineDNA DamageDNA RepairEnzyme ActivationGamma RaysGenes, Tumor SuppressorHumansMicePhosphatidylinositol 3-KinasesPhosphoric Monoester HydrolasesProto-Oncogene ProteinsAKT1 protein, humanAkt1 protein, ratCDC2 Protein KinasePhosphatidylinositol 3-KinasesPhosphoric Monoester HydrolasesProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycPTEN PhosphohydrolasePTEN protein, humanRecombinant Fusion ProteinsTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID12391152
PMCPMC134727
OpenAlexW2126718734

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.